Market Place
Sourcing Support
Meitheal Acquires Contepo From Nabriva To Expand Specialty Biopharma Portfolio
24 Jul 2024 //
INDIANPHARMAPOST
Meitheal Acquires CONTEPO From Nabriva Therapeutics
18 Jul 2024 //
BUSINESSWIRE
Century, Elevation to cut assets, staff; Nabriva winds down
06 Jan 2023 //
FIERCE BIOTECH
Nabriva Therapeutics Provides Corporate Update
06 Jan 2023 //
GLOBENEWSWIRE
Nabriva Announces Positive Results from Phase 1 Trial of XENLETA® (lefamulin)
28 Nov 2022 //
GLOBENEWSWIRE
Nabriva halts R&D, lays off 40% of staff in commercial refocus
11 Nov 2022 //
FIERCEBIOTECH
Nabriva Therapeutics Pivoting Strategic Focus Reports 3Q Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Nabriva Therapeutics to Report 3Q 2022 Financial Results and Recent Corporate
07 Nov 2022 //
GLOBENEWSWIRE
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
15 Sep 2022 //
GLOBENEWSWIRE
Nabriva Therapeutics to Participate in the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA®
11 Aug 2022 //
GLOBENEWSWIRE
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results
03 Aug 2022 //
GLOBENEWSWIRE
Nabriva Tx to Report Q2 2022 Financial Results
20 Jul 2022 //
GLOBENEWSWIRE
Nabriva Tx Expands XENLETA Presence with Excl. Agreement with Er-Kim Pharma
18 Jul 2022 //
GLOBENEWSWIRE
Nabriva Therapeutics to Present at H.C. Wainwright Global Investment Conference
13 May 2022 //
GLOBENEWSWIRE
Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO
05 May 2022 //
GLOBENEWSWIRE
Nabriva Therapeutics Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Nabriva Therapeutics to Report First Quarter 2022 Financial Results
02 May 2022 //
GLOBENEWSWIRE
Nabriva Begins Enrollment in PI Trial of XENLETA for Cystic Fibrosis
11 Apr 2022 //
GLOBENEWSWIRE
Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
Nabriva Tx to Report 2021 Financial Results on March 29, 2022
15 Mar 2022 //
GLOBENEWSWIRE
Nabriva Tx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2022 //
GLOBENEWSWIRE
Nabriva Tx Provides Business Update, Announces Preliminary Financial Results
10 Jan 2022 //
GLOBENEWSWIRE
Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders
22 Dec 2021 //
GLOBENEWSWIRE
Lefamulin NDA Filed in Mainland China for Treatment of Community
29 Nov 2021 //
GLOBENEWSWIRE
Nabriva Announces Availability of XENLETA in a 10-Count Oral Pack
11 Nov 2021 //
GLOBENEWSWIRE
Nabriva Therapeutics Reports Third Quarter 2021 Financial Results
09 Nov 2021 //
GLOBENEWSWIRE
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq
01 Nov 2021 //
GLOBENEWSWIRE
Nabriva to Report Third Quarter 2021 Financial Results and Recent Corporate
26 Oct 2021 //
GLOBENEWSWIRE
Nabriva Publishes Data DemonstratingAnti-Inflammatory Properties of XENLETA®
04 Oct 2021 //
GLOBENEWSWIRE
Nabriva Publishes Data DemonstratingAnti-Inflammatory Properties of XENLETA®
04 Oct 2021 //
GLOBENEWSWIRE
Nabriva Therapeutics to Present Data at IDWeek 2021
24 Sep 2021 //
GLOBENEWSWIRE
Nabriva & Vizient Ink Agreement to Make XENLETA Available to Vizient’s Pharmacy
09 Sep 2021 //
BIOSPACE
Nabriva shares rise after Xenleta approval in Taiwan
08 Sep 2021 //
SEEKING ALPHA
Lefamulin Receives Approval in Taiwan for Community-Acquired Pneumonia
08 Sep 2021 //
GLOBENEWSWIRE
Nabriva Therapeutics gets Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2021 //
GLOBENEWSWIRE
Nabriva Therapeutics Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Nabriva Second Quarter 2021 Financial Results Corporate Highlights August 5
22 Jul 2021 //
GLOBENEWSWIRE
Nabriva Second Quarter 2021 Financial Results Corporate Highlights
22 Jul 2021 //
GLOBENEWSWIRE
Nabriva Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Jul 2021 //
GLOBENEWSWIRE
Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results
25 May 2021 //
GLOBENEWSWIRE
Nabriva Commences Exclusive Distribution of SIVEXTRO®
15 Apr 2021 //
YAHOO
Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient
16 Mar 2021 //
GLOBENEWSWIRE
Nabriva and Sinovant Sciences Restructure License Agreement for XENLETA
07 Dec 2020 //
BIOSPACE
Nabriva and Sinovant Sciences Restructure License Agreement for XENLETA
07 Dec 2020 //
GLOBENEWSWIRE
Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age
13 Oct 2020 //
GLOBENEWSWIRE
Nabriva Therapeutics secures new reimbursement for Xenleta and Contepo
09 Sep 2020 //
SEEKINGALPHA
Nabriva Enters into Exclusive Agreement to Promote Distribute SIVEXTRO®
15 Jul 2020 //
GLOBENEWSWIRE
Nabriva hit with 2nd FDA complete response letter for Contepo
23 Jun 2020 //
FIERCE PHARMA
FDA Cites Travel Restrictions in CRL
22 Jun 2020 //
PHARMTECH
Nabriva Receives Complete Response Letter from FDA on NDA for (fosfomycin)
21 Jun 2020 //
BIOSPACE
Nabriva Receives Complete Response Letter from FDA on NDA for CONTEPO
19 Jun 2020 //
GLOBE NEWSWIRE
National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the US
18 May 2020 //
GLOBENEWSWIRE
XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response
05 May 2020 //
GLOBENEWSWIRE
Centers for Medicare & Medicaid Services Issues Product-Specific J-Code XENLETA
09 Apr 2020 //
BUSINESSINSIDER
Nabriva Therapeutics Receives FDA Acknowledgement of NDA Resubmission
08 Jan 2020 //
GLOBE NEWSWIRE
Nabriva Therapeutics Receives FDA Acknowledgement of NDA Resubmission
07 Jan 2020 //
GLOBE NEWSWIRE
Nabriva Therapeutics Receives FDA Acknowledgement of NDA Resubmission
07 Jan 2020 //
GLOBE NEWSWIRE
Nabriva Therapeutics Resubmits NDA for Intravenous fosfomycin for Injection
20 Dec 2019 //
GLOBENEWS WIRE
